• uniQure reported third quarter 2026 revenue of US$5.2 million and a net loss of US$61.22 million, alongside FDA acceptance and Priority Review of its Biologics License Application for ifezuntirgene inilparvovec in Huntington’s disease.
• The FDA’s Priority Review and alignment on a 200 patient confirmatory trial highlight how uniQure’s clinical execution and regulatory planning intersect with a cash intensive operating profile.
• Investors will now see how uniQure’s investment narrative could be reshaped by FDA Priority Review of its Huntington’s gene therapy.

Seize this moment around uniQure’s Huntington’s therapy momentum to compare it with a curated 36 healthcare AI stocks that are also working on high-impact treatments at…